Interview with: Steven S. Porter, Chairman and CEO - featuring: their novel anti-infective drugs based on its proprietary class of compounds, Ceragenins(TM) (or CSAs).

Ceragenix Pharmaceuticals, Inc.(CGXP-OTC: BB)

CURRENT ISSUE    |   COVER ARCHIVES    |       INDEX      |    CONTACT    |    FINANCIALS    |     MARKETING SERVICES   |    HOME PAGE

CEOCFO-Members Login
Become A Member!

Click on photo below for
Media Player audio of interview!

Steven S. Porter
Chairman and CEO

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
July 20, 2006

This is a printer friendly page!
Healthcare
Biopharma

Ceragenix Pharmaceuticals, Inc.(CGXP-OTC: BB)

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“We have a very unique competitive position; we have near term commercialization opportunities with profound technologies that have multiple applications that afford us a variety of commercialization pathways.” - Steven S. Porter